摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(苯氧基甲基)哌啶盐酸盐 | 63608-13-9

中文名称
4-(苯氧基甲基)哌啶盐酸盐
中文别名
4-(苯氧基甲基)哌啶
英文名称
4-(phenoxymethyl)piperidine hydrochloride
英文别名
4-(phenoxymethyl)piperidine;hydrochloride
4-(苯氧基甲基)哌啶盐酸盐化学式
CAS
63608-13-9
化学式
C12H17NO*ClH
mdl
MFCD09879196
分子量
227.734
InChiKey
XRWWXZPTHSCQPJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.92
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    25.8
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
  • 危险性描述:
    H315,H319,H335

SDS

SDS:a4402b177d044c892e99d05d0ad662eb
查看

反应信息

  • 作为反应物:
    描述:
    4-(苯氧基甲基)哌啶盐酸盐3-[(2-甲基-2-丙基)氧基]-2-吡嗪甲醛 以74%的产率得到2-tert-Butoxy-3-[4-(phenoxymethyl)piperidino]methyl-pyrazine
    参考文献:
    名称:
    Nitrogen containing heterocyclic compounds and medicines containing the same
    摘要:
    由以下一般式表示的化合物: 1 (其中X 1 、X 2 、X 3 和X 4 分别独立表示单键,C 1-6 烷基等;A 2 表示可选择地取代的苯基等;A 1 表示可选择地取代的含有—C(═Q 1 )—的5-至7-成员杂环基团(其中Q 1 表示氧、硫或═N—R 11 (其中R 11 表示氢或C 1-6 烷基))和氮等;以及Z 1 表示哌啶二基等),以及其盐和上述化合物的水合物。
    公开号:
    US20040167224A1
  • 作为产物:
    参考文献:
    名称:
    Piperazine derivatives for the treatment of urinary incontinence and pain
    摘要:
    公开号:
    EP1849773B1
点击查看最新优质反应信息

文献信息

  • 4-Phenoxymethyl-piperidines
    申请人:Boehringer Mannheim GmbH
    公开号:US04243807A1
    公开(公告)日:1981-01-06
    4-Phenoxymethyl-piperidines of the formula ##STR1## wherein R is hydrogen, halogen, nitro, lower alkyl or lower alkoxy, in the form of the free base or an acid addition salt, are provided and they are useful as intermediates in the production of anti-hypertensive agents through condensation with (a) propyl chloride and then with an adenine, or (b) a propyl indole.
    提供式子为##STR1##的4-苯氧甲基哌啶,其中R为氢、卤素、硝基、低烷基或低烷氧基,以自由碱或酸盐形式存在,它们可作为中间体用于通过与(a)丙基氯化物和腺嘌呤或(b)丙基吲哚缩合制备抗高血压药物。
  • Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound
    申请人:Ishii Takahiro
    公开号:US20100009971A1
    公开(公告)日:2010-01-14
    A novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound or its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound of the present disclosure is also useful in the treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.
    一种新型的吡啶基非芳香性含氮杂环-1-羧酸酯化合物或其药学上可接受的盐具有强效的FAAH抑制活性。此外,本公开的吡啶基非芳香性含氮杂环-1-羧酸酯化合物也可用于治疗尿频、尿失禁、过度活跃的膀胱和/或疼痛。
  • Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative
    申请人:Ishii Takahiro
    公开号:US20080306046A1
    公开(公告)日:2008-12-11
    [Problem] To provide a compound usable for treatment of diseases associated with fatty acid amide hydrolase (FAAH), especially for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain. [Means for Solution] We have found that a novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative of the present invention has an excellent effect for increasing an effective bladder capacity, an excellent effect for relieving urinary frequency and an excellent anti-allodynia effect, and is therefore usable for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.
    [问题] 提供一种可用于治疗与脂肪酸酰胺水解酶(FAAH)相关的疾病的化合物,特别是用于治疗尿频和尿失禁、过度活跃的膀胱和/或疼痛。 [解决方法] 我们发现一种新型的吡啶基非芳香性含氮杂环-1-羧酸酯衍生物及其药学上可接受的盐具有强效的FAAH抑制活性。此外,本发明的吡啶基非芳香性含氮杂环-1-羧酸酯衍生物具有优异的增加有效膀胱容量的效果,优异的缓解尿频的效果和优异的抗痛觉过敏效果,因此可用于治疗尿频和尿失禁、过度活跃的膀胱和/或疼痛。
  • NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF
    申请人:Eisai Co., Ltd.
    公开号:EP1484327A1
    公开(公告)日:2004-12-08
    Compounds represented by the following general formula: [wherein X1, X2, X3 and X4 each independently represent a single bond, C1-6 alkylene, etc.; A2 represents optionally substituted phenyl, etc.; A1 represents an optionally substituted 5- to 7-membered heterocyclic group containing -C(=Q1)- (wherein Q1 represents oxygen, sulfur or =N-R11 (wherein R11 represents hydrogen or C1-6 alkyl)) and nitrogen, etc.; and Z1 represents piperidin-diyl, etc.], salts thereof and hydrates of the foregoing.
    由以下通式代表的化合物: [其中 X1、X2、X3 和 X4 各自独立地代表单键、C1-6 亚烷基等;A2 代表任选取代的苯基等;A1 代表含有-C(=Q1)-(其中 Q1 代表氧、硫或=N-R11(其中 R11 代表氢或 C1-6 烷基))和氮等的任选取代的 5 至 7 元杂环基团;Z1 代表哌啶二基等]、 其盐和上述物质的水合物。
  • PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE
    申请人:Astellas Pharma Inc.
    公开号:EP1849773A1
    公开(公告)日:2007-10-31
    [Problem] To provide a compound usable for treatment of diseases associated with fatty acid amide hydrolase (FAAH), especially for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain. [Means for Solution] We have found that a novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative of the present invention has an excellent effect for increasing an effective bladder capacity, an excellent effect for relieving urinary frequency and an excellent anti-allodynia effect, and is therefore usable for treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.
    [问题]提供一种可用于治疗与脂肪酸酰胺水解酶(FAAH)相关疾病的化合物,特别是用于治疗尿频和尿失禁、膀胱过度活动症和/或疼痛。 [解决方法]我们发现,一种新型吡啶基非芳香族含氮杂环-1-羧酸酯衍生物及其药学上可接受的盐具有强效的 FAAH 抑制活性。此外,本发明的吡啶基非芳香族含氮杂环-1-羧酸酯衍生物在增加有效膀胱容量方面效果显著,在缓解尿频方面效果显著,在抗排尿障碍方面效果显著,因此可用于治疗尿频和尿失禁、膀胱过度活动症和/或疼痛。
查看更多